news

CUPERTINO, Calif., Sept. 30, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat hosted by Ed Arce of H. C. Wainwright on Monday, October 5, 2020 from […]

CUPERTINO, Calif., Sept. 23, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival

Phase 2b study in subjects with Alcoholic Hepatitis to evaluate safety and efFIcacy of DUR-928 treatMent (AHFIRM) CUPERTINO, Calif., Sept. 22, 2020 /PRNewswire/ — DURECT Corporation (NASDAQ: DRRX) today announced the study design for the Phase 2b AHFIRM clinical trial of DUR-928 in severe alcoholic hepatitis (AH) patients. AHFIRM is a randomized, double-blind, placebo-controlled, international, multi-center

CUPERTINO, Calif., Sept. 10, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will participate in the HC Wainwright 22nd Annual Global Investment Conference, Cantor Fitzgerald Virtual Global Healthcare Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. HC Wainwright 22nd Annual Global Investment ConferenceDate                     Monday, September 14 Time:                    2:30-2:50 PM EDT (Fireside Chat with Ed Arce)Webcast:

CUPERTINO, Calif., Aug. 27, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the presentation of pharmacokinetic (PK) data from a Phase 2a study of DUR-928 in alcoholic hepatitis (AH) at the Digital International Liver Congress™ 2020 (EASL), taking place on August 27-29.  DUR-928 was well tolerated at all doses tested in 19 AH patients, including 12

CUPERTINO, Calif., Aug. 26, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat hosted by Ellie Merle of Cantor Fitzgerald, tomorrow, Thursday, August 27, 2020 at 11:00

CUPERTINO, Calif., Aug. 5, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat at the BTIG Biotechnology Conference 2020, Monday, August 10, 2020 at 11:00 a.m. EDT

Live Webcast of Earnings Call Today, August 3rd at 4:30 p.m. ET CUPERTINO, Calif., Aug. 3, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2020 and provided a corporate update. Total revenues were $25.8 million and net income was $14.3 million for the three months ended

CUPERTINO, Calif., July 28, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter 2020 financial results and host a conference call after the market close on Monday, August 3, 2020. Monday, August 3 @ 4:30pm Eastern Time / 1:30 p.m. Pacific Time Toll Free:                   877-407-0784 International:              201-689-8560 Conference ID:            13706541 Webcast:                      http://public.viavid.com/index.php?id=140595

– U.S. Food and Drug Administration (FDA) has authorized the investigational new drug (IND) application – Acute liver and kidney injury are risk factors for poor outcomes in COVID-19 patients – The risk of death from multi-organ failure is present in both patients with severe COVID-19 and those with severe Alcoholic Hepatitis (AH) – Promising Phase 2a clinical